Brexafemme (ibrexafungerp) / SCYNEXIS, R-Pharm, Jiangsu Hansoh Pharma, GSK - LARVOL DELTA

In Vitro Synergy between Amphotericin B and Ibrexafungerp against Talaromyces marneffei (IDWeek 2026) - No abstract available

Preclinical • Infectious Disease

Real-World Effectiveness of Ibrexafungerp in Patients with Vulvovaginal Candidiasis (IDWeek 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Candidiasis • Infectious Disease

In Vitro Synergy between Amphotericin B and Ibrexafungerp against Talaromyces marneffei (IDWeek 2026) - No abstract available

Preclinical • Infectious Disease

Pathogenesis and Triazole Resistance in Aspergillus fumigatus: A Narrative Review Across the Host Immune Spectrum and One Health Context. (PubMed, Infect Drug Resist) - "Novel antifungal agents, such as olorofim, fosmanogepix, rezafungin, ibrexafungerp, and T-2307, along with targeted delivery and immunomodulatory adjunct therapies for resistant aspergillosis, are also summarized. Major knowledge gaps persist regarding horizontal gene transfer of resistance mutations, cross-species transmission chains, and translational applications of environmental monitoring data. This review summarizes existing research bottlenecks and proposes integrated multi-sector prevention and control strategies from a One Health perspective to curb the growing threat of triazole-resistant aspergillosis."

Journal • Review • Gene Therapies • Pulmonary Disease • Respiratory Diseases • ARAF

Fungal Esophagitis: Molecular Insights Into Pathogenesis and Emerging Antifungal Strategies. (PubMed, Front Biosci (Landmark Ed)) - "While fluconazole remains the first-line agent for most cases, the increasing prevalence of non-albicans Candida species and drug resistance underscore the importance of alternative medications with different molecular targets. Agents such as the recently approved rezafungin as well as compounds such as ibrexafungerp and fosmanogepix, represent promising options for the treatment of refractory disease. This review synthesizes current advances in the molecular pathogenesis of fungal esophagitis, with particular emphasis on host-fungal interactions, antifungal resistance mechanisms, and novel treatment strategies. A deeper understanding of these processes is essential to improve management and to guide the development of innovative immunomodulatory and antifungal therapies."

IO biomarker • Journal • Review • Eosinophilic Esophagitis • Gastrointestinal Disorder • Human Immunodeficiency Virus • Immunology • Infectious Disease • Oncology • Solid Organ Transplantation • Transplantation • IL17A

Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives. (PubMed, Eur J Med Chem) - "This narrative review summarizes the current landscape of emerging antifungal therapies, focusing on ibrexafungerp 1, rezafungin 2, fosmanogepix 3, olorofim 4, opelconazole 5, and oteseconazole 6. However, important challenges remain, including limited activity against Mucorales for several agents, the potential emergence of future resistance, and the need for additional comparative clinical data and real-world experience. Overall, the expanding antifungal pipeline represents a major advancement toward more targeted and individualized antifungal therapy and may significantly reshape the future management of invasive and refractory fungal infections."

Journal • Review • Candidiasis • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Candida auris: a review of global epidemiology, multidrug resistance, and infection control in healthcare-associated outbreaks. (PubMed, Front Cell Infect Microbiol) - "Analysis of 80 peer-reviewed studies reveals five principal findings: (1) C. auris exhibits clade-dependent geographic distribution and resistance profiles-Clade I (South Asia) and Clade III show fluconazole resistance exceeding 90%, whereas Clade IV exhibits 44% resistance; echinocandin resistance varies significantly by clade and no resistance was detected in certain clades; amphotericin B resistance varies from no detected resistance to 46% depending on clade; and pan-resistant strains have emerged; (2) biofilm-associated C. auris cells (sessile cells) exhibit MBECs 2- to 4,119-fold higher than planktonic MICs, representing a major driver of persistent colonization; (3) novel antifungal agents, including ibrexafungerp, manogepix (the active moiety of fosmanogepix), and rezafungin, demonstrate promising in vitro activity against C. auris, with manogepix showing the highest overall antibiofilm activity (geometric mean MBEC of 5.9 μg/mL) and ibrexafungerp demonstrating..."

Journal • Review • Infectious Disease

Green spectrofluorimetric determination of Ibrexafungerp using NBD-Cl derivatization. (PubMed, Sci Rep) - "The method was successfully applied without interference from excipients. Greenness assessment using Analytical Eco-Scale, AGREE, and GAPI tools confirmed the environmentally friendly nature of the proposed method, supporting its suitability for routine quality control applications."

Journal • Candidiasis • Vaginitis

Synergistic Liposomal Delivery of Ibrexafungerp Citrate and Marine-Sourced Silver Nanoparticles for Effective Management of Vulvovaginal Candidiasis. (PubMed, J Funct Biomater) - "Ultimately, this study successfully developed an eco-friendly liposomal formulation co-loaded with AN-AgNPs and IBC, offering a promising and targeted therapeutic approach for the treatment of vulvovaginal candidiasis."

Journal • Candidiasis • Vaginitis

New Perspectives on Antimicrobial Agents: Fosmanogepix. (PubMed, Antimicrob Agents Chemother) - "Novel first-in-class antifungal agents have been recently approved (ibrexafungerp) or are currently being tested in clinical trials and are available via expanded access programs (olorofim, fosmanogepix). Novel gepix compounds have been developed and could make their niche in the future (e.g., APX2039, prodrug: APX2096, for cryptococcal meningitis, and APX2020, prodrug: APX2097, for coccidioidomycosis). This review discusses the future place of fosmanogepix in the antifungal armamentarium against IFIs."

Journal • Candidiasis • CNS Disorders • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Wild-type MIC distributions and Epidemiological Cut-off Values for Ibrexafungerp, Manogepix, and Rezafungin against WHO Fungal Priority Pathogens. (PubMed, Int J Antimicrob Agents) - "For other WHO-listed pathogens, particularly filamentous and dimorphic fungi, data remained insufficient for robust analysis. The ECVs and T-ECVs derived herein provide crucial reference points to guide future resistance surveillance and inform the foundational epidemiology needed for clinical breakpoint setting."

Journal • Review

Advances in vulvovaginal candidiasis research: a comprehensive review from epidemiology, diagnosis, treatment to resistance mechanisms. (PubMed, Front Microbiol) - "Second, antifungal susceptibility testing should be interpreted with attention to vaginal pH conditions, and non-azole alternatives (boric acid, nystatin, ibrexafungerp, oteseconazole) should be prioritized when azole resistance is confirmed or suspected. By integrating these contemporary findings, this review provides a translational framework to optimize diagnosis, guide therapeutic decision-making, and inform future research priorities in VVC management. Notably, several novel agents-including ibrexafungerp and oteseconazole-have already received FDA approval and are entering clinical practice, with multiple ongoing trials evaluating boric acid, probiotics, and novel oral antifungals, underscoring the accelerating translation of mechanism-informed therapies into patient care."

Journal • Review • Candidiasis • Infectious Disease • Vaginitis

Multicenter surveillance of antifungal susceptibility of clinical Aspergillus isolates to conventional and novel antifungal agents in Taiwan, 2021-2023. (PubMed, Microbiol Spectr) - "Members of the Aspergillus niger clade exhibited reduced susceptibility to itraconazole and isavuconazole. Anidulafungin, along with novel antifungals including orolofim, manogepix, and rezafungin, demonstrated broad activity across Aspergillus species, including those with intrinsic or acquired azole resistance...Novel antifungals, including orolofim, manogepix, rezafungin, and ibrexafungerp, demonstrated broad activity across Aspergillus species, including resistant isolates. Nevertheless, the inhaled agent opelconazole exhibited limited activity against A. flavus regardless of voriconazole susceptibility and against other species showing reduced susceptibility to itraconazole. These findings highlight the importance of species-level identification, susceptibility testing, and continued surveillance and support the use of novel antifungals for aspergillosis."

Clinical • Journal • Pulmonary Disease • Respiratory Diseases

The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis. (PubMed, Infect Drug Resist) - "Rezafungin holds promise as an excellent option for outpatient antimicrobial therapy programs due to its favorable safety profile and convenient once-weekly dosing. Ibrexafungerp has broad-spectrum antifungal activity, including activity against fluconazole- and echinocandin-resistant Candida spp...Fosmanogepix has a novel mechanism of action, a favorable side-effect profile, and a broad spectrum of clinical activity. However, further data from clinical trials are necessary to further establish its role in the management of invasive candidiasis. The role of agents in early clinical development, including BAL2062 and ATI2307, as well as repurposed agents with antifungal activity, such as miltefosine, in the management of invasive candidiasis remains to be determined."

Journal • Review • Candidiasis

New antifungals for the treatment of invasive mold disease. (PubMed, Clin Microbiol Infect) - "Development of new antifungal agents is challenging due to limited target sites, emergence of resistance, and adverse toxicity profiles. However, clinical data from fosmanogepix, olorofim, and encochleated amphotericin B are promising in both clinical efficacy and safety for the treatment of invasive mold infections. These new agents offer alternative options for difficult to treat infections, while providing promising efficacy and improved safety outcomes."

Journal • Review • Infectious Disease

The Silent Pandemic: Antifungal Resistance and the Future of Invasive Fungal Disease Management. (PubMed, Microorganisms) - "We critically appraise the diagnostic gap between phenotypic testing and clinical urgency, highlighting the role of rapid molecular assays and next-generation sequencing. Finally, we evaluate evidence-based therapeutic strategies, including the integration of novel agents such as rezafungin, ibrexafungerp, olorofim, and fosmanogepix), while emphasizing the imperative of antifungal stewardship, infection prevention and control in mitigating resistance, and "One-Health" interventions."

Journal • Review • Infectious Disease

Past, present, and emerging antifungals against Fusarium and other rare non-aspergillus hyalohyphomycetes: a narrative review. (PubMed, Expert Opin Pharmacother) - "Both rezafungin and ibrexafungerp have limited efficacy and clinical experience in treating mold infections. Fosmanogepix and olorofim hold promise for treating invasive mold infections, including hyalohyphomycoses; however, given in-vitro antifungal susceptibility variability against hyalohyphomycetes, and lack of clinical trial information, future studies are needed."

Journal • Review • Candidiasis • Infectious Disease

In vitro activities of ibrexafungerp and comparators against Candida bloodstream isolates in Taiwan (ESCMID Global 2026) - No abstract available

Preclinical

Comprehensive Review of Candidozyma (Candida) auris Management: Insights From the Society of Infectious Diseases Pharmacists. (PubMed, Pharmacotherapy) - "The role of triazoles and amphotericin B is significantly limited by resistance and associated toxicities, while newer agents such as ibrexafungerp, fosmanogepix, and rezafungin show promising in vitro activity but lack substantial supporting clinical data. Despite growing awareness, effective decolonization strategies are lacking, and recurrence and transmission continue to pose challenges. Ongoing efforts to refine antifungal therapy, improve rapid diagnostics, and strengthen infection control practices are essential to mitigating the spread of this pathogen and optimizing outcomes for patients."

Journal • Review • CNS Disorders • Infectious Disease • Psychiatry

Novel antifungal compounds against Fusarium spp: A systematic review. (PubMed, Enferm Infecc Microbiol Clin (Engl Ed)) - "The antifungals reported were manogepix (10), olorofim (3), ibrexafungerp (1), and MGCD290 (1), evaluated against 480 Fusarium isolates. Ibrexafungerp and MGCD290 did not show good activity as monotherapy. Further work on applications and development of new treatments against the resistant Fusarium species is essential."

Journal • Review

Innovations in the management of Candida infections (PubMed, Dtsch Med Wochenschr) - "The newly licensed echinocandin Rezafungin broadens the therapeutic options available for invasive candidiasis. Ibrexafungerp and Fosmanogepix are promising alternative treatment options for systemic Candida infections in late-stage clinical development."

Journal • Review • Candidiasis • Infectious Disease

Improvement of enfumafungin production by Hormonema carpetanum via mutagenesis and process optimization: mutant generation and preliminary transcriptomic analysis. (PubMed, World J Microbiol Biotechnol) - "Enfumafungin, a triterpenoid antifungal compound, serves as the key starting material for the synthesis of ibrexafungerp and SCY-247...Furthermore, batch fermentation of ENF-5-29 in a 5 L bioreactor achieved a yield of 1,621 mg/L, the highest yield reported to date. Our results demonstrate the efficacy of mutagenesis for H. carpetanum improvement and pinpoint key targets for future genetic engineering aimed at enhancing enfumafungin biosynthesis."

Journal

Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents. (PubMed, J Fungi (Basel)) - "We assess the efficacy and safety of established antifungal agents alongside the breakthrough introduction of novel drug classes, with a particular interest in the oral triterpenoid ibrexafungerp and the tetrazole oteseconazole, which offer new mechanisms of action for cases that fail to respond to standard regimens. Furthermore, we address the management of a special clinical scenarios, including pregnancy and lactation, and explore promising emerging innovative approaches such as mucoadhesive formulations, immunomodulatory approaches, and alternative non-antifungal therapies. Ultimately, this review aims to support clinical decision-making by balancing the accessibility and user-friendliness of conventional treatments with the targeted precision offered by modern antifungal agents."

Journal • Review • Candidiasis • Vaginitis

The challenges of Candidozyma auris: updates on the laboratory investigation, infection prevention and management. (PubMed, Future Microbiol) - "Given the issues with multi-drug resistance, studies exploring the use of ibrexafungerp and fosmanogepix alone or in combination with echinocandins are urgently needed. In addition to evaluating combination therapy and newer antifungals, future priorities for C. auris include increasing global awareness, the development of accessible, rapid diagnostic methods and antifungal susceptibility methodology, investigation of optimal disinfection strategies, and clinical studies better characterizing clinical outcomes."

Journal • Review • Candidiasis • Infectious Disease

Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation. (PubMed, J Antimicrob Chemother) - "This review synthesizes current evidence and recommendations for antifungal TDM across available and emerging agents, including triazoles, flucytosine, echinocandins, amphotericin B, and novel therapies such as ibrexafungerp, olorofim and fosmanogepix. Voriconazole, posaconazole and itraconazole exhibit substantial interpatient variability and concentration-dependent toxicity, supporting routine TDM. Fluconazole is generally predictable but may warrant monitoring in critically ill patients, those on renal replacement therapy, or with central nervous system infections, though empiric dose escalation is often more practical. Isavuconazole has more stable PK, limiting TDM to select high-risk scenarios...Liposomal amphotericin B exhibits complex PK with plasma concentrations poorly reflecting active drug, precluding reliable TDM...Despite strong justification, real-world utilization remains inconsistent, constrained by access, logistics and interpretive challenges. Expanding..."

Journal • Review • Infectious Disease • Obesity • Renal Disease